Potential Treatment of the Superbugs (MRSA, C.Diff) Infections in a Hospitalized Population

Online, August 30, 2010 (Newswire.com) - A Potential Treatment of the "Superbug"
(MRSA; C. Difficile) Infection in a Hospitalized Population
Inventor: Alfred T. Sapse, M.D. (r), Las Vegas, NV

This treatment is based upon a synergistic combination of an antibiotic plus a cortisol modulator that would add to the strength of the antibiotic, a more vigorous response by the patient's own immune system.

This treatment has already been used in a double blind study in an AIDS population mostly resistant to the AIDS cocktail treatments. This study was carried out in two groups of AIDS patients, one group receiving the AIDS cocktail plus placebo and the other group receiving the AIDS cocktail plus the cortisol modulator.

The results had shown that there were no improvements in the AIDS cocktail / placebo group, as a matter of fact, some of the patients were actually deteriorating; the group that received the AIDS cocktail / cortisol modulator showed improvement at statistically significant levels on the majority of end points targeted.

Cortisol, the hormone manufactured by the adrenal gland, was found in elevated immune suppressive levels in the blood of the "superbug"patients indicating a serious break of the immune resistance.

As such, the role of the immune modulators partnering with antibiotics makes sense and becomes more pertinent now as we are witnessing a slow but dangerous transition from "superbugs" afflicting the general population (AIDS and others) people with an assumably good immune response, to a hospitalized population with an already weakened immune resistance.

Cortisol Modulators: Drugs that are capable of reducing cortisol levels in the blood which were previously elevated.

For more information, pleas consult two papers in the medical press, namely 1. Sapse, A.T., Stress, Cortisol, Interferon and Stress Diseases, Medical Hypotheses, 13, 31-44, 1984, Glasgow, UK and Sapse, A.T., Cortisol, High Cortisol Diseases, and Anti-Cortisol Therapy, Psychoneuroendocrinology, vol. 22 (Supplement ) pp. S3-510, 1997, Oxford Univ.

Contact:

Alfred T. Sapse, M.D. (r)
1701 E. Katie Avenue #20
Las Vegas, NV 89119
Tel: (702) 734-6814 Fax: (702)733-9505
Cell: (702) 688-3065
E-Mail: [email protected]
Website: www.kronosiv.co.uk

Company Profile:

The company is focusing on four areas: (1) the treatment of Alzheimer's Disease (AD) by activating the dormant / inactive stem cells in the hippocampus (the memory center of the brain) and the targeted area of Alzheimer's; (2) the treatment of Superbugs (infectious diseases), focusing on the treatment of resistant diseases, such as AIDS, in the general population and on antibiotic resistant diseases such as the Superbug (MRSA) (C. Diff.); (3) the treatment of obesity by using cholesterol absorption inhibitors (CAI) agents that would prevent the exogenous (outside) cholesterol from penetrating the body and starting the process of obesity; and (4) A joint project with the Department of Urology UCLA (Prof. Nestor Gonzalez-Cadavid) intended to activate the dormant stem cells in the penile area and restore some activity in an E.D. population.